From: Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer
 | n | % | RFS1 (P) | BRD2 (P) |  | n | % | RFS (P) | BRD (P) |
---|---|---|---|---|---|---|---|---|---|
T stage | Â | Â | 0.003 | 0.001 | Ad chemo TX 4 | Â | Â | 0.201 | 0.759 |
T1 | 229 | 56.7 | Â | Â | Yes | 150 | 37.1 | Â | Â |
T2 | 155 | 38.4 | Â | Â | No | 254 | 62.9 | Â | Â |
T3 | 12 | 3.0 | Â | Â | Ad rad TX 5 | Â | Â | 0.851 | 0.906 |
T4 | 8 | 2.0 | Â | Â | Yes | 295 | 73.0 | Â | Â |
N stage | Â | Â | 0.036 | 0.001 | No | 109 | 27.0 | Â | Â |
N0 | 261 | 64.6 | Â | Â | Ad hor TX 6 | Â | Â | 0.921 | 0.644 |
N1 | 99 | 24.5 | Â | Â | Yes | 192 | 47.5 | Â | Â |
N2 | 42 | 10.4 | Â | Â | No | 212 | 52.5 | Â | Â |
N3 | 2 | 0.5 | Â | Â | Age | Continuous | 0.905 | 0.335 | Â |
Stage | Â | Â | 0.008 | 0.001 | Menopausal status | Â | Â | 0.541 | 0.773 |
I | 178 | 44.1 | Â | Â | Pre | 119 | 29.5 | Â | Â |
IIA | 122 | 30.2 | Â | Â | Post | 212 | 52.5 | Â | Â |
IIB | 53 | 12.3 | Â | Â | CTC | Â | Â | 0.029 | 0.001 |
IIIA | 40 | 10.4 | Â | Â | Yes | 76 | 18.8 | Â | Â |
IIIB | 9 | 1.7 | Â | Â | No | 328 | 81.2 | Â | Â |
IIIC | 2 | 0.5 | Â | Â | Recurrence | Â | Â | Â | Â |
Histology | Â | Â | 0.933 | 0.440 | Yes | 54 | 13.4 | Â | Â |
Lobular | 44 | 10.9 | Â | Â | No | 350 | 86.6 | Â | Â |
Ductal | 341 | 84.4 | Â | Â | Mortality | Â | Â | Â | Â |
Other | 19 | 4.7 | Â | Â | Yes | 34 | 8.4 | Â | Â |
Differentiation | Â | Â | <0.001 | <0.001 | No | 370 | 19.6 | Â | Â |
I | 98 | 24.3 | Â | Â | BC mortality 7 | Â | Â | Â | Â |
II | 185 | 45.8 | Â | Â | Yes | 25 | 6.2 | Â | Â |
III | 121 | 30.0 | Â | Â | No | 379 | 93.8 | Â | Â |
ER 1 | Â | Â | 0.029 | <0.001 | Follow-up | Â | Â | Â | Â |
Pos | 342 | 84.7 | Â | Â | min | 6 months | Â | Â | Â |
Neg | 62 | 15.3 | Â | Â | max | 90 months | Â | Â | Â |
PR 2 | Â | Â | 0.061 | 0.001 | mean | 48.6 months | Â | Â | Â |
Pos | 290 | 71.8 | Â | Â | median | 48 months | Â | Â | Â |
Neg | 114 | 28.2 | Â | Â | Â | Â | Â | Â | Â |
Her2/neu 3 | Â | Â | 0.024 | 0.010 | Â | Â | Â | Â | Â |
Pos | 81 | 20.0 | Â | Â | Â | Â | Â | Â | Â |
Neg | 323 | 80.0 | Â | Â | Â | Â | Â | Â | Â |